CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2015—FIND, a Geneva-based nonprofit organization, and QuantuMDx Group, a British medical device developer, are joining forces to develop a solution for the combined detection of and drug susceptibility determination for the causative agent for tuberculosis. Based on the molecular detection of an extensive set of genetic markers by the handheld QuantuMDx Q-POC device, the time for full antimycobacterial-resistance profiling will be reduced from one week to less than half an hour. The nanowire technology developed by QuantuMDx provides the potential to interrogate the bacterial genome with precision, as it allows the targeted detection of specific markers and, in a future evolution of the present system, genetic sequencing on the same technology platform. As part of this partnership, FIND is supporting the development of an appropriate and integrated sample-handling compartment, while QuantuMDx continues its platform development.
QuantuMDx Group, 44 (0) 870 803 1234